Evidence check: Homocystein in the context of menopause

Homocysteine is a sulfur-containing amino acid derivative produced during methionine metabolism. During menopause, declining estrogen levels can affect homocysteine metabolism: estrogen promotes remethylation of homocysteine to methionine, so lower estrogen may lead to higher homocysteine. Elevated homocysteine is considered an independent risk factor for cardiovascular disease, which becomes more common after menopause. Evidence comes from observational studies and meta-analyses showing a moderate association, but causality is not firmly established. Genetic variants (e.g., MTHFR) can influence homocysteine levels; DNA tests can identify these, but effect sizes are small. Clinical relevance for individual menopause management is limited – a blood test for homocysteine is more informative. Supplementation with folate, B12, and B6 can lower homocysteine, but benefit for primary cardiovascular prevention is not clearly proven. Caution: very high levels (>30 µmol/L) warrant medical investigation. Overall, evidence is moderate – homocysteine is a biomarker, not a standalone decision tool.